Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020 (The Oncologist)

with Mollie F Qian, Nicolas J Betancourt, Nolan J Maloney, Kevin A Nguyen, Sunil A Reddy, Evan T Hall, Susan M Swetter, and Lisa C Zaba

Last updated on Sep 17, 2023

Widespread implementation of immune checkpoint inhibitors (ICI) and targeted therapies for metastatic melanoma has led to a decline in melanoma-related mortality but increased healthcare costs. We aimed to determine how healthcare utilization varied by systemic, non-adjuvant melanoma treatment from 2016 to 2020.

Alain Pineda
Alain Pineda
Research Economist

My research interests include informal employment, labor market trajectories, and inequality.